`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`
`v.
`
`ADAPT PHARMA LTD, and
`OPIANT PHARMACEUTICALS, INC.,
`Patent Owners.
`__________________
`
`Case No. IPR2019-00692
`U.S. Patent No. 9,561,177
`__________________
`
`MANDATORY NOTICES OF
`PATENT OWNER OPIANT PHARMACEUTICALS, INC.
`
`
`
`Case No. IPR2019-00692
`U.S. Patent No. 9,561,177
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Opiant Pharmaceuticals, Inc.
`
`(“Opiant”) submits the following mandatory notices:
`
`I.
`
`Real Parties in Interest, 37 C.F.R. § 42.8(b)(1)
`
`Adapt Pharma Limited (“Adapt”) and Opiant and are the assignees, and
`
`Adapt Pharma Operations Limited, a wholly owned subsidiary of Adapt, is a
`
`limited exclusive licensee, of U.S. Patent No. 9,561,177 and U.S. Patent No.
`
`9,775,838. Opiant is the assignee, and Adapt Pharma Operations Limited is a
`
`limited exclusive licensee, of U.S. Patent No. 9,211,253; U.S. Patent No.
`
`9,468,747; and U.S. Patent No. 9,629,965.
`
`Adapt is a wholly owned subsidiary of Emergent Acquisitions Limited.
`
`Emergent Acquisitions Limited is a wholly owned subsidiary of Emergent
`
`International Inc., which is a wholly owned subsidiary of Emergent BioSolutions
`
`Inc. Emergent BioSolutions Inc. is a publicly held company, and no publicly held
`
`company owns 10% or more of Emergent BioSolutions Inc.’s stock. Opiant is a
`
`publicly held company, and no publicly held company owns 10% or more of
`
`Opiant’s stock.
`
`II.
`
`Related Matters, 37 C.F.R. § 42.8(b)(2)
`
`Petitioner Nalox-1 Pharmaceuticals, LLC (“Nalox-1”) has filed the
`
`following related petitions for inter partes review:
`
`U.S. Patent No.
`9,211,253
`
`Case No.
`IPR2019-00685
`
`1
`
`
`
`Case No. IPR2019-00692
`U.S. Patent No. 9,561,177
`
`U.S. Patent No.
`9,211,253
`9,211,253
`9,468,747
`9,468,747
`9,468,747
`9,561,177
`9,561,177
`9,561,177
`9,629,965
`9,629,965
`9,629,965
`9,775,838
`9,775,838
`9,775,838
`
`Case No.
`IPR2019-00686
`IPR2019-00687
`IPR2019-00688
`IPR2019-00689
`IPR2019-00690
`IPR2019-00691
`IPR2019-00692
`IPR2019-00693
`IPR2019-00694
`IPR2019-00695
`IPR2019-00696
`IPR2019-00697
`IPR2019-00698
`IPR2019-00699
`
`U.S. Patent No. 9,211,253; U.S. Patent No. 9,468,747; U.S. Patent No.
`
`9,561,177; U.S. Patent No. 9,629,965; and U.S. Patent No. 9,775,838 are being
`
`asserted in Adapt Pharma Operations Ltd., et al. v. Teva Pharmaceuticals USA,
`
`Inc., et al., Case 2:16-cv-07721-JLL-JAD (D.N.J.) (consolidated), filed October
`
`21, 2016; and Adapt Pharma Operations Ltd., et al. v. Perrigo UK FINCO Limited
`
`Partnership, Case 2:18-cv-15287-JLL-JAD (D.N.J.), filed October 25, 2018.
`
`Administrative matters that would be or could be affected by this proceeding
`
`include pending U.S. Patent Application Nos. 15/415,221; 15/494,270; and
`
`16/131,641.
`
`2
`
`
`
`III. Lead & Backup Counsel, 37 C.F.R. § 42.8(b)(3)
`
`Opiant designates the following counsel:
`
`Case No. IPR2019-00692
`U.S. Patent No. 9,561,177
`
`LEAD COUNSEL
`
`Robert F. Green
`Reg. No. 27,555
`Green, Griffith & Borg-Breen LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`Phone: (312) 883-8000
`Fax: (312) 883-8001
`rgreen@greengriffith.com
`
`BACKUP COUNSEL
`
`Jessica Tyrus Mackay
`Reg. No. 64,742
`Green, Griffith & Borg-Breen LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`Phone: (312) 883-8000
`Fax: (312) 883-8001
`jmackay@greengriffith.com
`
`A power of attorney appointing the foregoing counsel to transact all business
`
`in this proceeding is being submitted together with this mandatory notice
`
`information.
`
`IV.
`
`Service Information, 37 C.F.R. § 42.8(b)(4)
`
`Counsel for Opiant submits the following service information:
`
`3
`
`
`
`Case No. IPR2019-00692
`U.S. Patent No. 9,561,177
`
`Electronic mail address:
`
`jmackay@greengriffith.com
`
`Postal mail address:
`
`Jessica Tyrus Mackay
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`
`Telephone number:
`
`(313) 883-8000
`
`Counsel for Opiant consents to electronic service by email at
`
`jmackay@greengriffith.com.
`
`Date: March 12, 2019
`
`Respectfully submitted,
`
` /Jessica Tyrus Mackay /
`Jessica Tyrus Mackay (Reg. No. 64,742)
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`(313) 883-8000
`jmackay@greengriffith.com
`
`Counsel for Patent Owner
`Opiant Pharmaceuticals, Inc.
`
`4
`
`
`
`Case No. IPR2019-00692
`U.S. Patent No. 9,561,177
`
`CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true
`
`and correct copy of the foregoing was served on March 12, 2019, by delivering a
`
`copy via electronic mail on the following attorneys of record:
`
`Jessamyn S. Berniker
`David M. Krinsky
`Anthony H. Sheh
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`jberniker@wc.com
`dkrinsky@wc.com
`asheh@wc.com
`tkenner@wc.com
`
`Yelee Y. Kim
`Janine A. Carlan
`Richard Berman
`Bradford Frese
`Christopher Yaen
`Arent Fox LLP
`1717 K Street NW
`Washington, DC 20036
`Yelee.Kim@arentfox.com
`Janine.Carlan@arentfox.com
`Richard.Berman@arentfox.com
`Bradford.Frese@arentfox.com
`Christopher.Yaen@arentfox.com
`
`
`
`
`
`/ Jessica Tyrus Mackay /
`Jessica Tyrus Mackay
`Reg. No. 64,742
`
`5
`
`